Related Experiment Videos
[Long-term results of the treatment of diffuse systemic scleroderma with interferon-gamma]
La Revue De Medecine Interne
|January 1, 1993
Abstract:
There are very few drugs effective in the treatment of diffuse scleroderma and therefore we conducted an open study with gamma interferon. Among 20 diffuse scleroderma, evolving since less than 3 years, an improvement was observed in 8 patients. There was no serious side effect. Survival of these 20 patients was 85% at 5 years.
Insights
Gamma interferon showed potential in treating diffuse scleroderma, with 8 of 20 patients improving and no serious side effects. This suggests a promising new avenue for managing this rare autoimmune disease.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Context:
- Diffuse scleroderma is a rare autoimmune disease with limited effective treatments.
- Early-stage diffuse scleroderma (evolving < 3 years) was the focus of this study.
- Gamma interferon is an immunomodulatory cytokine with potential therapeutic applications.
Purpose:
- To evaluate the efficacy and safety of gamma interferon in patients with early-stage diffuse scleroderma.
Summary:
- An open study was conducted on 20 patients with diffuse scleroderma evolving for less than 3 years.
- Gamma interferon treatment resulted in observed improvement in 8 out of 20 patients.
- No serious adverse events were reported during the study.
- Five-year survival rate for the studied cohort was 85%.
Impact:
- Gamma interferon demonstrates potential as a treatment option for diffuse scleroderma.
- The study highlights the need for further research into immunomodulatory therapies for autoimmune conditions.
- Findings suggest a possible improvement in patient outcomes and survival rates.